

# Neoadjuvant chemotherapy in breast cancer patients induces expression of tumor suppressor miR-34a

Pierre Frères<sup>1\*</sup>, Claire Josse<sup>1</sup>, Nicolas Bovy<sup>2</sup>, Meriem Boukerroucha<sup>3</sup>, Ingrid Struman<sup>2</sup>, Vincent Bours<sup>3</sup>, Guy Jerusalem<sup>1</sup>


<sup>1</sup> University of Liège, Laboratory of Medical Oncology, Liège, Belgium

<sup>2</sup> University of Liège, GIGA-Research, Unit of Molecular Biology and Genetic Engineering, Liège, Belgium


<sup>3</sup> University of Liège, GIGA-Research, Human Genetics, Liège, Belgium

Circulating microRNAs (miRNAs) are extensively studied in cancer as biomarkers but little is known about the influence of anti-cancer drugs on their expression. In this presentation, we describe the modifications of circulating miRNAs profile under neoadjuvant chemotherapy (NAC) for breast cancer.


## Methods and results




**Figure 1.** Bland-Altman plot of the variations of circulating miRNAs at the end of the NAC. Expression of 188 circulating miRNAs was determined by RT-qPCR in 25 patients before and after NAC. Relative expression is normalized to the 50 most expressed miRNAs.



**Figure 2.** Expression of miR-34a was determined by RT-qPCR and in-situ hybridization in the tumor tissue of 7 patients with partial pathological response (pPR) to NAC. Relative expression is normalized to RNU 44, RNU 48 and cel-miR-39.




**Figure 3.** Comparisons of circulating miR-34a in NAC treated patients with pathological complete response (pCR,  $n = 5$ , in red) and pPR ( $n = 6$ , in blue).



**Figure 4.** Kinetic of circulating miR-34a variations under NAC. Blood samples were withdrawn before therapies (NA1), after 1 or 2 cycles of anthracycline (NA2), 1 week before surgery (D-8) and 3 months after surgery (3M). Data are expressed as mean  $\pm$  SEM.

### Correlation between upregulation of plasma miR-34a and troponins T



**Figure 5.** Pearson and Spearman correlation between fold-change (NA1 vs. NA2) of miR-34a and troponins T ( $p < 0.05$ ,  $r = 0.4673$ ,  $n = 25$ ) in plasma of patients with NAC.

## Conclusions

NAC induces expression of miR-34a in plasma and tumor tissue, which could be a **predictive marker** of response to NAC in aggressive tumors. Moreover, chemo-induced miR-34a may be involved in **anti-tumor effect and cardiotoxicity** of chemotherapy agents.